Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its fiscal 2025 10-K annual report with the SEC on Feb 27, 2026. It reported revenue of $213M (+1.6% year over year) and net income of −$59M.
FY2025 key financial metrics · XBRL
- Revenue
- $213M
- +1.6% YoY
- Net income
- −$59M
- −5.8% YoY
- Operating margin
- -25.5%
- +1.1 pp YoY
- Gross margin
- 79.8%
- −0.6 pp YoY
- EPS (diluted)
- −$0.93
- −3.3% YoY
- ROE
- -67.6%
- −18.2 pp YoY
- Operating cash flow
- −$16M
- +57.0% YoY
Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) FY2025 10-K on SEC EDGAR. USD.
TREACE MEDICAL CONCEPTS, INC. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
- New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
- Strategic shift: Addressing surgeon shift to minimally invasive bunion surgery with lower-priced new product lines; growing stocking distributor sales (from $0 to $13M in 2025)
- Quantitative highlights: Active surgeons increased 6% to 3,337; direct sales force generated 80% of 2025 revenue; marketable securities $37.7M; legal expenses up $5.4M due to patent infringement lawsuits
- Noteworthy fact: Filed multiple patent infringement lawsuits in 2024-2025 against major competitors Stryker and Zimmer Biomet over Lapiplasty 3D technology
Management Discussion & Analysis
- Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
- Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
- Best segment: not segmented; gross profit stable at $169.8M vs $168.3M; no segment-level details; worst metric: net loss deepening
- Operating cash flow use $16.0M in 2025 vs $37.2M in 2024; investing cash inflow $13.3M in 2025 driven by sales/maturities of securities; financing cash inflow $2.1M in 2025 primarily from new term loan net proceeds ($59.3M) and repayments of prior loans ($56.3M)
- Management expects existing cash, securities ($10.7M + $37.7M), and credit facilities sufficient for 12+ months; potential need to raise additional capital to support growth and operational needs; risks include market acceptance, competition, supply chain, economic factors, and litigation impacts
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.